
-
Asian stocks rise on trade deal hopes, Tokyo hit by Trump warning
-
Thailand's PM suspended by Constitutional Court
-
Blur will return to musical oasis, says drummer Rowntree
-
CBEX crypto scam: AI-hyped Ponzi scheme defrauds African investors
-
Inzaghi hails 'extraordinary' Al Hilal after City upset
-
Man City, Inter Milan crash out of Club World Cup in last 16
-
North Korea's Kim shown honouring troops killed in Russia-Ukraine war
-
Saudi's Al Hilal knock Man City out of Club World Cup in huge shock
-
'In our blood': Egyptian women reclaim belly dance from stigma
-
Online memorial for children dead in Hiroshima, Nagasaki
-
US Senate in final push to pass Trump spending bill
-
Asian stocks rise on trade deal hopes, Tokyo hit by tariff warning
-
Hong Kong rights record under fire as it marks China handover anniversary
-
Bangladeshis cling to protest dreams a year after revolution
-
Djokovic, Sinner enter Wimbledon fray
-
European security tops Denmark's EU presidency priorities
-
France expecting peak temperatures as heatwave hits Europe
-
Germany eye return to women's football summit at Euro 2025
-
'Every day I see land disappear': Suriname's battle to keep sea at bay
-
England feel pressure to perform at Euros as stars pull out
-
Clashes in Istanbul over alleged 'Prophet Mohammed' cartoon
-
India face 'last-minute' Bumrah call as they bid to level England series
-
Dortmund up against 'superstar' Ramos, aggressive Monterrey: Kovac
-
US judge orders Argentina to sell 51% stake in oil firm YPF
-
Pantheon Resources PLC Announces Change of Registered Office
-
EPA employees accuse Trump administration of 'ignoring' science
-
US Senate in final slog towards vote on Trump spending bill
-
Over 14 million people could die from US foreign aid cuts: study
-
End of the line for Britain's royal train
-
FIFPro warns of 'wake-up call' over extreme heat at Club World Cup
-
Sean Combs sex trafficking jury ends first day without decision
-
Fluminense stun Inter Milan to reach Club World Cup quarters
-
Thailand's ruling political dynasty faces day of legal peril
-
NASA eyes summer streaming liftoff on Netflix
-
Trump dismantles Syria sanctions program as Israel ties eyed
-
Meta's AI talent war raises questions about strategy
-
Twenty bodies, some headless, found in Mexican cartel bastion
-
Gaza rescuers say Israeli forces kill over 50 as ceasefire calls mount
-
Alcaraz survives scare, Sabalenka cruises on Wimbledon's hottest opening day
-
Only Messi can shirk defending: warns Monterrey coach before Dortmund clash
-
White House says Canada 'caved' to Trump on tech tax
-
Eight-country coalition aims to tax luxury air travel
-
Wimbledon qualifier Tarvet vows to get creative with expenses
-
Iran unleashes 'wave of repression' after Israel war: activists
-
Alcaraz survives Fognini scare to launch Wimbledon title defence
-
Peace deal with Rwanda opens way to 'new era', says DR Congo president
-
Kneecap, Bob Vylan Glastonbury sets spark police probe and global criticism
-
'Starvation' days over as cyclists prepare to gorge on Tour de France
-
Gaza rescuers say Israeli forces kill 48 as ceasefire calls mount
-
Sabalenka boosted by hitting with Djokovic and Sinner at Wimbledon

From Covid to cancer: High hopes for Nobel mRNA vaccines
The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
- How does it work? -
Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
- Where did this come from? -
The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
- What else can mRNA do? -
Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
G.Stevens--AMWN